Arcus Biosciences Appoints Rekha Hemrajani as Chief Operating and Financial Officer
25 Março 2019 - 5:10PM
Business Wire
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage
biopharmaceutical company focused on creating innovative cancer
immunotherapies, today announced the appointment of Rekha Hemrajani
as Chief Operating and Financial Officer. Ms. Hemrajani will be
responsible for several key areas, including finance, investor
relations, corporate communications, business and corporate
development, strategic planning and human resources.
“We are thrilled to welcome Rekha as a key member of our senior
leadership team, as we enter an exciting period in Arcus’s
development with multiple Phase 1 readouts for AB928, our dual
A2a/A2b receptor antagonist, AB154, our anti-TIGIT antibody, and
AB680, our small-molecule CD73 inhibitor,” said Terry Rosen, Ph.D.,
Chief Executive Officer of Arcus. “Rekha has an extraordinary track
record in the life sciences and biotechnology industries, and her
broad experience will be invaluable as we focus on advancing this
slate of product candidates.”
“I am excited to join Arcus at this key point in its evolution,
with four promising therapeutics in clinical development and a
myriad of opportunities to translate the potential of the company’s
pipeline into meaningful benefit for cancer patients,” commented
Ms. Hemrajani. “I look forward to working with the Arcus team to
make the best decisions based on the steady flow of data and
results this year.”
With more than 20 years of experience in the biotechnology
industry, Ms. Hemrajani brings extensive expertise in all aspects
of corporate and business development, financing and strategic
planning. Ms. Hemrajani joins Arcus from FLX Bio where she was
Chief Operating Officer, with responsibility for corporate strategy
and development, investor and media relations, corporate
communications, finance and strategic marketing. Prior to FLX Bio,
Ms. Hemrajani was Chief Financial Officer and Senior Vice President
of Business and Financial Operations at 3-V Biosciences.
Previously, Ms. Hemrajani was Vice President, Head of Licensing and
Mergers and Acquisitions at Onyx Pharmaceuticals and Vice President
of Business Development at Exelixis, where she was involved in
transactions that generated $800M in upfront and committed funding
for the company. Ms. Hemrajani began her career in investment
banking at firms such as Credit Suisse First Boston and Lehman
Brothers, where she focused on the biopharmaceutical and healthcare
sector.
Ms. Hemrajani received her B.S. degree in Economics and Computer
Science from the University of Michigan and her M.B.A. from the
Kellogg Graduate School of Management at Northwestern
University.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company
focused on creating innovative cancer immunotherapies. Arcus
has several programs targeting important immuno-oncology pathways,
including a dual adenosine receptor antagonist, AB928, which is in
a Phase 1/1b program to evaluate AB928 in combination with other
agents in multiple tumor types, and an anti-PD-1 antibody, AB122,
which is being evaluated in a Phase 1 trial and is being tested in
combination with Arcus’s other product candidates. Arcus’s other
programs include AB154, an anti-TIGIT antibody, which is being
evaluated in a Phase 1 trial as monotherapy and in combination with
AB122, and AB680, a small-molecule inhibitor of CD73, which is in a
Phase 1 healthy volunteer study. Arcus has extensive in-house
expertise in medicinal chemistry, immunology, biochemistry,
pharmacology and structural biology. For more information about
Arcus Biosciences, please visit www.arcusbio.com.
Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including, but not limited to, Arcus’s clinical
development plans, pipeline and timelines are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause Arcus’s
actual results, performance or achievements to differ significantly
from those expressed or implied. Factors that could cause or
contribute to such differences include, but are not limited to, the
inherent uncertainty associated with pharmaceutical product
development and clinical trials, the emergence of adverse events or
other undesirable side effects and delays in our clinical trials
due to difficulties or delays in the regulatory process, enrolling
subjects or manufacturing or supplying product for such clinical
trials. Risks and uncertainties facing Arcus are described more
fully in Arcus’s Annual Report on Form 10-K for the year ended
December 31, 2018 filed on March 5, 2019 with the SEC. You are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date of this press release.
Arcus disclaims any obligation or undertaking to update, supplement
or revise any forward-looking statements contained in this press
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190325005525/en/
Nicole Arndt(510) 284-4728narndt@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024